DIAGNOSTIC TECHNIQUE FOR ALZHEIMER DISEASE BY MEASURING CHEMICALLY MODIFIED FORMS OF METAL-BINDING BETA-AMYLOID DOMAIN IN BIOLOGICAL FLUIDS

摘要

FIELD: medicine.;SUBSTANCE: invention refers to diagnostic technique in medicine and describes a laboratory diagnostic technique for Alzheimer disease by using metal-binding domain modified 1-16 forms of human beta-amyloid as Alzheimer disease pathogenesis biomarkers. The method is characterised by the fact that total peptide fraction, then beta-amyloid fraction and fragments of 1-16 beta-amyloid fraction to be further analysed after the targeted proteolysis is recovered from a denatured sample of biological fluid, urine, cerebrospinal fluid. If the biological fluid sample appears to contain a metal-binding domain modified, asparlic acid isomerised (position 7) form of beta-amyloid in the relative amount of more than 5% of the total amount of the 1-16 beta-amyloid fraction and/or a metal-binding domain modified, serine phosphorylated (position 8) form of beta-amyloid, Alzheimer disease is diagnosed.;EFFECT: invention can be used to establish a diagnosis of Alzheimer disease.;1 ex